Biopharma BD&L: the tsunami is upon us
Pharma’s business development and licensing (BD&L) teams are at the forefront of identifying new science to support their company’s future. As the biopharma industry navigates an increasingly complex marketplace, traditional approaches to identifying and evaluating potential drug candidates are showing signs of strain.
How to improve biopharma business development with AI-powered due diligence
Biopharma business development and scientific teams are under a lot of pressure to identify the next big program for their indication and strategy.
Chinese biotechs & assets, a Q&A with Kanya Rajangam, MD, PhD
Recently, I had a conversation with Dr. Kanya Rajangam, to discuss current perceptions about Chinese biotech, opportunities, language challenges, and risks.
AI for biopharma business development: finding the right assets faster
By combining human expertise with AI-powered analysis, we’re helping biopharma companies make faster, more informed business development decisions.
Biotech Limited Partners: learnings from investing in biotech venture capital funds
Limited Partners (LPs) are at the heart of the biotech funding ecosystem—these crucial players ignite the funding flywheel that drives biotech innovation.
